GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Inc (NAS:INBX) » Definitions » Market Cap

Inhibrx (Inhibrx) Market Cap : $940.61 Mil (As of Jun. 04, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Inhibrx Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Inhibrx's share price for the quarter that ended in Mar. 2024 was $31.3958. Inhibrx's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 49.23 Mil. Therefore, Inhibrx's market cap for the quarter that ended in Mar. 2024 was $1,545.75 Mil.

Inhibrx's quarterly market cap increased from Sep. 2023 ($779.31 Mil) to Dec. 2023 ($1,616.53 Mil) but then declined from Dec. 2023 ($1,616.53 Mil) to Mar. 2024 ($1,545.75 Mil).

Inhibrx's annual market cap declined from Dec. 2021 ($1,529.16 Mil) to Dec. 2022 ($963.99 Mil) but then increased from Dec. 2022 ($963.99 Mil) to Dec. 2023 ($1,616.53 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Inhibrx's Enterprise Value for Today is $1,566.23 Mil.


Inhibrx Market Cap Historical Data

The historical data trend for Inhibrx's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Market Cap Chart

Inhibrx Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial - 1,116.62 1,529.16 963.99 1,616.53

Inhibrx Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 738.77 1,018.04 779.31 1,616.53 1,545.75

Competitive Comparison of Inhibrx's Market Cap

For the Biotechnology subindustry, Inhibrx's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inhibrx's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibrx's Market Cap distribution charts can be found below:

* The bar in red indicates where Inhibrx's Market Cap falls into.



Inhibrx Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Inhibrx's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$34.1259*47.3695
=$1,616.53

Inhibrx's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=$31.3958*49.2342
=$1,545.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inhibrx  (NAS:INBX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Inhibrx Market Cap Related Terms

Thank you for viewing the detailed overview of Inhibrx's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Inhibrx (Inhibrx) Business Description

Traded in Other Exchanges
N/A
Address
11025 N. Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
Executives
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Mark Lappe director, 10 percent owner, officer: Chief Executive Officer 11622 EL CAMINO REAL, SUITE 100, SAN DIEGO CA 92130
Brendan P. Eckelman director, 10 percent owner, officer: Chief Scientific Officer C/O INHIBRX, INC., 11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jon Faiz Kayyem director, 10 percent owner 5964 LA PLACE COURT, CARLSBAD CA 92008
Dragsa 50 Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Portfolio Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Kristiina Md Vuori director C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Klaus W. Wagner officer: Chief Medical Officer C/O INHIBRX, INC., 11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Kimberly Manhard director C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121